February 23, 2012

Virologic and Immunologic Monitoring of Cytomegalovirus to Guide Preemptive Therapy in Solid-Organ Transplantation


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

There is increasing literature on immunologic monitoring for cytomegalovirus (CMV) post-transplant in order to guide antiviral therapy.  Assays used for immune monitoring include the Quantiferon-CMV, ELISpot, and flow cytometry-based quantitation of CMV-specific T-cells.  In this study, 134 SOT patients had immunologic monitoring by flow cytometry as well as CMV viral loads.  At 1 year after transplant, the majority of patients (89%) had CMV-specific immunity.  The presence of both CD4+ and CD8+ T cell immunity correlated with the ability to control CMV viremia.  This study shows the importance of measurement of CMV-specific immunity although much work needs to be done to standardize immune function assays before they can be used clinically.

Transplant Infectious Disease

Tags: , ,